Tempus ECG-AF vs VX1+
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A, Tempus ECG-AF, is designed for pre-procedural risk assessment, identifying patients aged 65 or older at increased risk of developing Atrial Fibrillation (AF) within 12 months using 12-lead ECGs. Conversely, Tool B, VX1+, is an intra-procedural tool that assists electrophysiologists in real-time identification of abnormal electrograms during cardiac ablation procedures for AF and Atrial Tachycardia. While both address AF within cardiology, their distinct focus on risk prediction versus real-time procedural guidance makes them adjacent rather than direct competitors.
Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your primary objective is to proactively identify patients aged 65 or older who are at an increased risk of developing new-onset atrial fibrillation within the next 12 months, particularly in a screening or general cardiology setting. This tool is ideal for early risk stratification and guiding follow-up for individuals without pre-existing AF, enabling earlier intervention.
View Tempus ECG-AF →Choose VX1+ if…
Choose VX1+ if you are an electrophysiologist performing cardiac ablation procedures for atrial fibrillation or atrial tachycardia and require real-time, AI-powered assistance to identify abnormal electrograms. This software is specifically designed to provide intra-procedural guidance, helping to pinpoint ablation targets and enhance the efficacy of the procedure.
View VX1+ →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Tempus ECG-AF | VX1+ |
|---|---|---|
| Pricing | Contact vendor | Unknown |
| Deployment | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. | Software, compatible with most multipolar catheters and mapping technologies used in operating rooms or electrophysiology labs. |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Yes AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Tempus ECG-AF | VX1+ |
|---|---|---|
| Name | Tempus ECG-AF | VX1+ |
| Primary Purpose | Analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up. | AI-powered software that assists electrophysiologists in real-time identification of abnormal electrograms during cardiac ablation procedures for atrial fibrillation and atrial tachycardia. |
| Company | Tempus AI, Inc. | Volta Medical |
| Target Use Case/Population | Patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery, for earlier identification and follow-up of new onset AF. | Electrophysiologists during cardiac ablation procedures for atrial fibrillation and atrial tachycardia. |
| Key AI Functionality | AI-based algorithm for 12-lead ECG analysis to detect signs associated with new onset Atrial Fibrillation (AF) within 12 months. | Real-time manual or automatic annotation of 3D anatomical and electrical maps; identification of spatio-temporal dispersed electrograms (DEs) during AF and AT procedures. |
| Supported Specialties | Cardiology, Geriatrics, Internal Medicine | Cardiology |
Videos
Demos, reviews, and walkthroughs featuring Tempus ECG-AF and VX1+.
Loading videos…
Videos need JavaScript to load. Search YouTube directly →
Frequently Asked Questions
Tempus ECG-AF is designed for earlier identification and follow-up of patients aged 65 or older at increased risk of developing AF within 12 months, fitting into a diagnostic or risk stratification phase. VX1+ assists electrophysiologists in real-time during cardiac ablation procedures for AF and atrial tachycardia, providing intra-procedural guidance.
Tempus ECG-AF is a software solution integrated into healthcare facility systems and is compatible with FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems. VX1+ integrates with existing EP recording and 3D mapping systems, specifically compatible with Boston Scientific LabSystem Pro, GE HealthCare MacLab CardioLab EP Recording System, and Abbott EnSite X 3D mapping system.
Tempus ECG-AF identifies patients at increased risk of developing AF within 12 months, with a sensitivity of 31% and specificity of 92% for classifying patients that developed clinically recognized AF, aiding in predictive risk assessment for earlier intervention. VX1+ assists electrophysiologists in real-time identification of abnormal electrograms during ablation procedures, offering a 'Booster mode' for increased sensitivity during AT or slow AF to guide procedural decisions.
Tempus ECG-AF is intended for Cardiology, Geriatrics, and Internal Medicine, focusing on patients aged 65 or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery. VX1+ is primarily for Electrophysiologists, assisting them during cardiac ablation procedures for patients with atrial fibrillation and atrial tachycardia.
Tempus ECG-AF is designed to integrate into existing ECG platforms and EHRs, likely operating without a dedicated user interface, with results presented for interpretation in conjunction with other clinical data. VX1+ features a simple user interface with color coding for electrogram dispersion and real-time annotation capabilities, suggesting an interactive and procedural learning curve for electrophysiologists during live procedures.
Tempus ECG-AF supports earlier identification and follow-up for patients at risk of AF, potentially leading to earlier management and improved long-term outcomes by flagging individuals for further evaluation. VX1+ aims to enhance procedural efficacy during ablation by providing real-time AI guidance to precisely pinpoint optimal ablation locations, which could lead to better treatment outcomes and potentially reduce recurrence rates for AF and AT.
More Comparisons
More matchups featuring Tempus ECG-AF or VX1+
Backers
Who funded each tool's parent company.